论文部分内容阅读
研究和比较国产与进口基因重组人红细胞生成素（ｒＨｕＥＰＯ）对长期血液透析（ＨＤ）慢性肾衰竭（ＣＲＦ）贫血患者的影响。将６０例长期血透慢性肾衰竭贫血病人随机分成２组，分别应用国产ｒＨｕＥＰＯ（益比奥）、进口ｒＨｕＥＰＯ（生血素）１００μｇ／（ｋｇ·周），均分３次治疗。２组患者在治疗第２周网织红细胞（ＲＲＢＣ）均显著上升，治疗１２周内血细胞比容（ＨＣＴ）均达到０．３０以上，且生活质量均有所改善。表明国产、进口ｒＨｕＥＰＯ疗效无显著性差异，均可安全、有效地改善ＣＲＦ患者贫血状态。
To study and compare the impact of domestic and imported recombinant human erythropoietin (rHuEPO) on patients with chronic hemodialysis (HD) chronic renal failure (CRF) anemia. Sixty chronic anemia patients with chronic hemodialysis patients with chronic renal failure were randomly divided into two groups. The patients were treated with rHuEPO (domestic) and 100 μg / (kg · weeks) rHuEPO respectively. Both groups had a significant increase of reticulocyte (RRBC) in the second week of treatment, and the HCT reached 0.30 within 12 weeks after treatment, and their quality of life improved. The results showed that the domestic and imported rHuEPO had no significant difference in the curative effect, which could safely and effectively ameliorate the anemia of CRF patients.